Down 62%, Should You Buy the Dip on Pfizer?
The narrative around Pfizer couldn't be much worse. That makes the stock very interesting at these prices.
Pharmaceutical giant Pfizer (NYSE: PFE) was a big winner during the COVID-19 pandemic. Its vaccine and antiviral pill generated billions of dollars in sales. However, that revenue source has largely dried up, and investors have shunned the stock since.
Pfizer stock has drifted lower since peaking in 2022 and sits over 63% off its former high following the market's recent sell-off.
I'll admit, Pfizer is dealing with a lousy narrative. Aside from the declines since the height of the pandemic, President Donald Trump's Secretary of Health and Human Services, Robert F. Kennedy Jr., has a public disdain for the pharmaceutical industry, and now investors are on edge in a highly volatile market.
